Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

Despite Published CDC Recommendations, Krintafel® is Not Indicated by the FDA for Use in Presumptive Anti-Relapse Therapy


News provided by

The Quinism Foundation

Feb 28, 2020, 17:00 ET

Share this article

Share toX

Share this article

Share toX

The U.S. Army celebrates the U.S. approval of tafenoquine (photo courtesy of the U.S. Army Medical Research and Materiel Command)
The U.S. Army celebrates the U.S. approval of tafenoquine (photo courtesy of the U.S. Army Medical Research and Materiel Command)

WHITE RIVER JUNCTION, Vt., Feb. 28, 2020 /PRNewswire-PRWeb/ -- The Quinism Foundation has sent correspondence to Evan Berland, at GlaxoSmithKline (GSK) Global Public Health, calling on GSK to take appropriate action to protect the health of asymptomatic U.S. travelers, including proposing further changes to the "Limitation of Use" section of the U.S. Prescribing Information for Krintafel®, to better emphasize that the drug is not indicated by the U.S. Food and Drug Administration (FDA) for presumptive anti-relapse therapy [1].

"Since the 2018 U.S. approval of Krintafel® for prevention of relapse of P. vivax infection in those receiving appropriate antimalarial therapy for acute P. vivax infection," wrote Remington Nevin, MD, MPH, DrPH, executive director of The Quinism Foundation, "the drug has been widely recommended for off-label use in presumptive anti-relapse therapy among asymptomatic U.S. travelers, including in published recommendations by the U.S. Centers for Disease Control and Prevention (CDC)."

GSK must take appropriate action to better emphasize that approved use of Krintafel® is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy

Post this

"Although the prevention of relapse of P. vivax malaria infection and presumptive anti-relapse therapy of asymptomatic travelers are clearly separate and distinct indications," Dr. Nevin noted, "CDC recommendations nonetheless confuse these terms, and even state erroneously use of Krintafel® in asymptomatic U.S. travelers for presumptive anti-relapse therapy 'is consistent with FDA labeling'."

In his correspondence, Dr. Nevin noted that in a "Dear Health Care Provider" letter, dated February 6, 2020 [2], GSK released data from a recent clinical trial that demonstrates that tafenoquine lacks efficacy in preventing P. vivax relapse when used with antimalarial drugs other than chloroquine. Dr. Nevin noted that the proposed change in the indication for Krintafel® as described by GSK in its "Dear Health Care Provider Letter", which would limit the use of the drug to co-administration with chloroquine only, has critical safety implications for use of the drug by asymptomatic U.S. travelers.

"CDC recommendations for Krintafel® to be co-administered with other drugs, such as atovaquone-proguanil and doxycycline that are commonly used by asymptomatic U.S. travelers for the prophylaxis of malaria," [3] Dr. Nevin wrote, would be "clearly at odds with the proposed change in indication for Krintafel®, which would limit the use of the drug to co-administration with chloroquine only, and presumably only at appropriate doses for treatment of acute P. vivax infection."

"Given that tafenoquine has been demonstrated to lack efficacy in preventing P. vivax relapse when used with antimalarial drugs other than chloroquine," Dr. Nevin noted, "current CDC recommendations for use of Krintafel® with other drugs in presumptive anti-relapse therapy may endanger asymptomatic U.S. travelers by placing them at risk of acute malaria from failed elimination of dormant hypnozoites. Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel® is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."

Dr. Nevin concluded his letter by recommending removal of the ambiguous term 'radical cure' from the U.S. Prescribing Information to reduce the risk of confusion between prevention of relapse and presumptive anti-relapse therapy.

"Tafenoquine, originally developed by the U.S. Army, is a member of a class of antimalarial drug known as 8-aminoquinolines found during World War II-era studies to be uniformly neurotoxic," said Dr. Nevin. "A leading researcher involved in testing of this class of drug in rhesus monkeys has noted 'all of nearly one hundred and forty 8-aminoquinolines examined… produce rather remarkable and highly specific lesions in the central nervous system [CNS].'" [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.

About The Quinism Foundation

The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the family of medical disorders caused by exposure to quinoline drugs, including mefloquine and tafenoquine.

Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist. He is author of more than 30 scientific publications on malaria and the quinoline antimalarials.

1. GSK. Krintafel® (Tafenoquine) U.S. Prescribing Information. July 2018.
2. GSK. Dear Health Care Provider Letter. February 6, 2020.
3. CDC. Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria – United States, 2019. MMWR. 2019;68(46):1062-1068.
4. Schmidt IG, Schmidt LH. Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey. Journal of neuropathology and experimental neurology. 1951;10(3):231-254.

SOURCE The Quinism Foundation

Modal title

The Quinism Foundation
The Quinism Foundation
The Quinism Foundation

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.